[Clinical and pharmacokinetic evaluation of cefsulodin in neonates and young infants].
Four neonates and young infants were treated with cefsulodin (CFS) at doses ranging from 20-25 mg/kg every 6 hours for 6.25 to 17 days, and clinical efficacy and side effects were evaluated. Among the 4 infants with bacterial infections including meningitis, bronchitis and pneumonia, the results were good in 2 patients with meningitis, but unknown in 2 patients because of additional use of gentamicin. One of the 4 patients had eosinophilia. Minimal inhibitory concentrations of CFS against 4 isolates of Pseudomonas aeruginosa were 1.56 against one and 12.5 micrograms/ml against other 3 strains with an inoculum size of 10(3) CFU. Serum concentrations of CFS were measured in one- and four-month-old infants upon 25.3 and 20.9 mg/kg bolus intravenous injection of the antibiotic, respectively. The values were 36.4 and 33.4 at 30 minutes, and 5.1 and 3.2 micrograms/ml at 6 hours after injection, respectively. Serum half-lives were 1.89 and 1.69 hours, respectively. Total body clearances and volume distributions were 3.16 and 3.76 ml/min/kg, and 519.0 and 551.2 ml/kg, respectively.
Fujita
K
K
Department of Pediatrics, Asahikawa Medical College.
Murono
K
K
Sakata
H
H
Yoshioka
H
H
D001991:Bronchitis / Q000188:drug therapy* / Q000378:metabolism; D002441:Cefsulodin / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008581:Meningitis / Q000188:drug therapy* / Q000378:metabolism; D011014:Pneumonia / Q000188:drug therapy* / Q000378:metabolism; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D013211:Staphylococcus aureus / Q000187:drug effects
D002441:Cefsulodin